All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Bristol Myers Squibb’s Breyanzi lymphoma application validated by EMA, scientific review process to begin
CAR-T cell therapy, lymphoma, cancer - Read more

THE GOOD
Business Development

SciSparc out-licences global rights of pain therapy SCI-160 to Polyrizon 
Small molecule, pain relief - Read more

THE GOOD
Clinical Trials

Walgreens and BARDA sign 5-year, $100M pact to increase access and diversity in decentralized clinical trials
Decentralized clinical trials, clinical trial design - Read more

CANbridge touts positive topline Ph3 data for CAN103 in Gaucher disease
Recombinant protein, Gaucher disease - Read more

BioNTech, MediLink Therapeutics’ Ph1 partial clinical hold for ADC BNT326/YL202 lifted by FDA
Antibody-drug conjugate, lung cancer, breast cancer - Read more

MindBio reports positive Ph2a data involving LSD microdosing regimen for major depressive disorder
Small molecule, psychedelic, major depressive disorder (MDD) - Read more

THE GOOD
Fundraises

Avidity Biosciences secures whopping $345.1M fundraise
Antibody-oligonucleotide conjugate, duchenne muscular dystrophy (DMD) - Read more

Janus Henderson’s $150M Biotech Innovation Fund II aims to invest in “small-cap public biotechs” according to Endpoints News Source [Paywall]
Biotech investing, venture capital - Read more

Phathom Pharmaceuticals $130M common stock offering
Small molecule, heartburn, gastroesophageal reflux disease (GERD) - Read more

THE GOOD
Investments

Accenture Ventures invests in Earli
Synthetic biopsy, cancer detection - Read more

THE GOOD
IPOs

TYK Medicines plans $74M IPO on the Hong Kong Stock Exchange; proceeds to support core asset TY-9591 clinical trials
Small molecule, lung cancer - Read more

PRESENTED BY THE UBC SCHOOL OF BIOMEDICAL ENGINEERING
Unlock the Future of Healthcare Innovation

Join us online on Wednesday, September 25th, at 5:30 PM Pacific for an information session about UBC's new Micro-certificate in Innovation Leadership: Medical & Bio-Innovations.

Discover how this transformative program equips you with essential legal, strategic, and practical skills to bridge the gap between scientific breakthroughs and market success.

What to Expect:

• Learn about the unique opportunities this program offers to advance your career.

• Understand how to make a meaningful impact on healthcare.

• Participate in a live Q&A session.

Don’t miss this opportunity—register now to secure your spot!🔗 

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Mergers & Acquisitions

Eli Lilly’s concludes $3.2B takeover of Morphic
Small molecule, inflammatory bowel disease (IBD) - Read more

Visiox Pharmaceuticals settles for acquisition by Ocuvex Therapeutics, 8 months after failed SPAC attempt
Small molecule, glaucoma, ocular hypertension - Read more

Genedata acquired by Danaher
Data analysis, research & development - Read more

THE GOOD
Partnerships

Sonnet BioTherapeutics enters into clinical trial collab with Sarcoma Oncology Center for SON-1210
Fusion protein, pancreatic cancer - Read more

Pirche, TCBalance Biopharmaceuticals Treg cell therapy R&D collaboration
Cell therapy, regulatory T cells, autoimmune - Read more

THE GOOD
Public Health

Bavarian Nordic slated to provide 10M Jynneos doses to Africa to combat current mpox outbreak
Vaccine, monkey pox (mpox) - Read more

THE GOOD
Strategic Plans

Eli Lilly’s external collab/innovation arm Lilly Catalyze360 has wide-reaching plans
External innovation, collaboration - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Liquidia’s tentative FDA approval for Yutrepia (US market access delayed until United Therapeutics’ exclusivity ends in May 2025) is less than INSPIRE-ng for investors, stock sinks 40%
Small molecule, pulmonary arterial hypertension (PAH), PH associated with with interstitial lung disease - Read more

THE UGLY
Lawsuits

Pfizer takes Ajanta Pharma to court over alleged patent infringement with generic versions of Xel­janz XR
Small molecule, autoimmune, rheuma­toid arthri­tis, ul­cer­a­tive col­i­tis, generic - Read more [Paywall]

THE UGLY
Withdrawals & Recalls

When are FDA med device recalls not actually recalls? More often than you think
Medical device - Read more 

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.